Migraine, Symbravo

FDA Approves Symbravo for Acute Treatment of Migraine in Adults
The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in
FDA approves new migraine treatment SYMBRAVO
NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue growth over the last twelve months, announced the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO®,
FDA Approves Symbravo for Acute Migraine Treatment
The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the treatment of acute migraine with or without aura in adults,
AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo
Emblaveo was jointly developed with Pfizer. AbbVie holds U.S. and Canada commercialization rights, with Pfizer responsible for commercialization in all other areas. Last April, the European Commission granted marketing authorization for treatment of adults with complicated intra-abdominal infections,
FDA Has Approved A New Medication Treatment For Migraines In Adults
Many people use the terms ‘migraine’ and ‘headache’ interchangeably. This leads many people to believe that migraines are not as serious as people make them out to be, and that cannot be more wrong, migraines have a major effect on a person’s lifestyle and the new approved medication may prove to be a great relief!
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday. AbbVie and co-developer Pfizer's drug, Emblaveo, is approved in combination with an antibiotic medication for patients 18 years and older with such infections.
Monthly Prescribing Reference5d
Symbravo Approved for Acute Treatment of Migraine With or Without Aura
The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.
FiercePharma9d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Yahoo Finance10h
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...
Pharm Exec9d
FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without Aura
Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...
Axsome Therapeutics announces FDA approval of Symbravo
Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in ...
RBC Capital lifts Axsome stock target to $143, sees launch potential
RBC Capital Markets analyst Leonid Timashev increased the price target for Axsome Therapeutics (NASDAQ:AXSM) to $143 from $139, while keeping an Outperform rating on the stock. According to ...